Fletikumab
Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis[2] that targets IL-20.[3]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | IL20 |
| Clinical data | |
| Other names | NNC0109-0012 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6494H10000N1728O2050S44 |
| Molar mass | 146492.12 g·mol−1 |
This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.
References
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
- Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.